Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 3
2016 1
2017 1
2018 1
2020 1
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Oesterheld J, et al. Among authors: bergendahl g. J Clin Oncol. 2024 Jan 1;42(1):90-102. doi: 10.1200/JCO.22.02875. Epub 2023 Oct 26. J Clin Oncol. 2024. PMID: 37883734 Free PMC article. Clinical Trial.
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
Saulnier-Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK. Saulnier-Sholler G, et al. Among authors: bergendahl g. Clin Cancer Res. 2022 Sep 15;28(18):3950-3957. doi: 10.1158/1078-0432.CCR-22-1169. Clin Cancer Res. 2022. PMID: 35833850 Free PMC article. Clinical Trial.
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. Eslin D, et al. Among authors: bergendahl g. Int J Cancer. 2023 Sep 1;153(5):1026-1034. doi: 10.1002/ijc.34569. Epub 2023 May 29. Int J Cancer. 2023. PMID: 37246577 Clinical Trial.
Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM. Sholler GLS, et al. Among authors: bergendahl g. Sci Rep. 2018 Sep 27;8(1):14445. doi: 10.1038/s41598-018-32659-w. Sci Rep. 2018. PMID: 30262852 Free PMC article. Clinical Trial.
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS, Bergendahl G, Lewis EC, Kraveka J, Ferguson W, Nagulapally AB, Dykema K, Brown VI, Isakoff MS, Junewick J, Mitchell D, Rawwas J, Roberts W, Eslin D, Oesterheld J, Wada RK, Pastakia D, Harrod V, Ginn K, Saab R, Bielamowicz K, Glover J, Chang E, Hanna GK, Enriquez D, Izatt T, Halperin RF, Moore A, Byron SA, Hendricks WPD, Trent JM. Sholler GLS, et al. Among authors: bergendahl g. Genome Med. 2024 Feb 12;16(1):28. doi: 10.1186/s13073-024-01297-5. Genome Med. 2024. PMID: 38347552 Free PMC article. Clinical Trial.
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Kraveka JM, Lewis EC, Bergendahl G, Ferguson W, Oesterheld J, Kim E, Nagulapally AB, Dykema KJ, Brown VI, Roberts WD, Mitchell D, Eslin D, Hanson D, Isakoff MS, Wada RK, Harrod VL, Rawwas J, Hanna G, Hendricks WPD, Byron SA, Snuderl M, Serrano J, Trent JM, Saulnier Sholler GL. Kraveka JM, et al. Among authors: bergendahl g. Cancer Rep (Hoboken). 2022 Nov;5(11):e1616. doi: 10.1002/cnr2.1616. Epub 2022 Mar 31. Cancer Rep (Hoboken). 2022. PMID: 35355452 Free PMC article.
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.
Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. Byron SA, et al. Among authors: bergendahl g. Cancer Res. 2021 Dec 1;81(23):5818-5832. doi: 10.1158/0008-5472.CAN-21-1033. Epub 2021 Oct 5. Cancer Res. 2021. PMID: 34610968 Free PMC article.
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. Lewis EC, et al. Among authors: bergendahl g. Int J Cancer. 2020 Dec 1;147(11):3152-3159. doi: 10.1002/ijc.33044. Epub 2020 May 24. Int J Cancer. 2020. PMID: 32391579 Free PMC article. Clinical Trial.
A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
Saulnier Sholler GL, Bergendahl GM, Brard L, Singh AP, Heath BW, Bingham PM, Ashikaga T, Kamen BA, Homans AC, Slavik MA, Lenox SR, Higgins TJ, Ferguson WS. Saulnier Sholler GL, et al. Among authors: bergendahl gm. J Pediatr Hematol Oncol. 2011 Jan;33(1):25-30. doi: 10.1097/MPH.0b013e3181f47061. J Pediatr Hematol Oncol. 2011. PMID: 21063221 Clinical Trial.
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J. Saulnier Sholler GL, et al. Among authors: bergendahl g. Cancer Med. 2015 Jun;4(6):871-86. doi: 10.1002/cam4.436. Epub 2015 Feb 26. Cancer Med. 2015. PMID: 25720842 Free PMC article.
13 results